Shield Therapeutics plc (STX) Ordinary Shares 1.5p
0.20p
(2.41%)
- Add to watchlist
- Create an alert
- This stock can be held in a
0.20p
(2.41%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
0.20p
(2.41%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
8.30p
8.46p
9.00p
£84.38 million
8.30p
8.00p
2.20p
n/a
0.70p (7.78%) Previous:
0.70p
1,861,131
n/a
150,000
Performance
| 1 week 1W | 5.06% | 1 year 1Y | 86.52% |
|---|---|---|---|
| 1 month 1M | 46.9% | 2 years 2Y | 18.02% |
| 3 months 3M | 228.71% | 3 years 3Y | 20.89% |
| 6 months 6M | 176.67% | 5 years 5Y | 91.67% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
| Year ending: | 31/12/2024 | 31/12/2023 |
|---|---|---|
| Revenue (£m) | 32.18 | 13.09 |
| Profit before tax (£m) | (26.56) | (32.38) |
| Adjusted EPS (p): | (3.00) | (5.00) |
| P/E ratio | n/a | n/a |
| PEG | n/a | n/a |
| EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Shield Therapeutics gets FDA priority review to extend Accrufer indication
4 September 2025 13:24
-
Shield Therapeutics reports sharp rise in first-half revenue
3 September 2025 13:06
-
Shield Therapeutics inks exclusive licence agreement in Japan
22 April 2025 09:03
-
£1.5 million placing supporting growth of ACCRUFeR
15 September 2025 07:00
-
ACCRUFeR® assigned Priority Review in US by FDA
4 September 2025 07:03
-
Interim results for the six months ended 30 Jun 25
3 September 2025 14:17
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.